Despite a slight slip in numbers for on-schedule postmarketing studies, FDA Commissioner Scott Gottlieb sounded a positive note when he reported the agency's progress in holding companies accountable.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,